| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| Mi | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 117 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 20.11. | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.11. | Vaso announces divestiture of VasoHealthcare for $0.8M | 1 | Seeking Alpha | ||
| 19.11. | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 378 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11. | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
| 14.11. | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 216 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 02.09. | Telescope Innovations Corp.: Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer | 380 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader... ► Artikel lesen | |
| 14.08. | Vasomedical reports Q2 results | 1 | Seeking Alpha | ||
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 262 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 240 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen | |
| 13.01. | Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors | 192 | GlobeNewswire (Europe) | PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 35,880 | +1,64 % | Bayer steigt weiter, Vonovia rutscht ab: DAX-Ausblick | Der DAX setzt seine Klettertour fort. In der abgelaufenen Handelswoche legte das größte deutsche Börsenbarometer unter dem Strich etwa 230 Punkte zu und schloss +0,97% höher mit 24.261 Punkten. Die... ► Artikel lesen | |
| ASTRAZENECA | 156,15 | +0,87 % | Astrazeneca und Daiichi Sankyo erhalten erweitere US-Zulassung für Enhertu | DJ Astrazeneca und Daiichi Sankyo erhalten erweitere US-Zulassung für Enhertu
Von Adria Calatayud
DOW JONES--Astrazeneca und Daiichi Sankyo haben in den USA die Zulassung für eine erweiterte... ► Artikel lesen | |
| EYEPOINT | 14,710 | -1,14 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| IONIS PHARMACEUTICALS | 67,58 | -0,53 % | Cathie Woods ARK Invest setzt Verkäufe bei Ionis Pharma fort | ||
| CSPC PHARMA | 0,890 | -1,37 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2085 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA | ||
| SELLAS LIFE SCIENCES | 2,010 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 23,220 | +0,09 % | Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright | ||
| CATALYST PHARMACEUTICALS | 20,780 | +2,42 % | Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock | ||
| MADRIGAL PHARMACEUTICALS | 498,20 | -1,23 % | MASH-Potenzial: Piper Sandler hebt Kursziel für Madrigal-Aktie auf 900 Dollar an | ||
| ENZON PHARMACEUTICALS | 0,032 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,698 | +0,12 % | Opus Genetics, Inc. - 8-K, Current Report | ||
| CHUGAI PHARMACEUTICAL | 44,340 | -1,23 % | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 5,150 | -0,96 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |